Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma

Phase 1 Completed 22 enrolled OncoPep, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and tolerability of PVX-410, (a cancer vaccine), treatment regimen for patients with smoldering multiple myeloma as a single agent and in combination with lenalidomide.

Timeline

Start: 2012-11
Primary completion: 2016-06
Completion: 2016-09

Publications

Nooka AK, Wang ML, Yee AJ, Kaufman JL, Bae J, Peterkin D, Richardson PG, Raje NS. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. JAMA Oncol. 2018 Dec 1;4(12):e183267. doi: 10.1001/jamaoncol.2018.3267. Epub 2018 Dec 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PVX-410	Vaccine	0.4 mg	Subcutaneous
Subject	PVX-410	Vaccine	0.8 mg	Subcutaneous

Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications